Daguang Wang

Daguang is the Managing Director of Yonjin Capital LLC, the North America and Europe investment arm of Yongjin Group in Shanghai, China. Before venture investment, Daguang spent more than 20 years in the biotech and pharmaceutical industry with Amgen, Memory Pharmaceuticals, EMD Serono and Sanofi. Daguang started his career as a research and development scientist in Neuroscience, working in the areas of Neurodegenerative diseases, Psychiatric disorders and Multiple Sclerosis, before moving to Business Development and External Innovation. Daguang was a global lead of Business Development and External Innovation for neuroscience at Sanofi before joining Yonjin in 2018. In addition to Evasc, Daguang is a board member of Hyperfine Research and GenomeDx.

‍

Daguang received his BS degree in Biochemistry from Jilin University in China, and his PhD in Molecular Genetics from the Washington University in St Louis in the US. Daguang conducted postdoctoral research at Stanford University with Professor Roger Kornberg.